HOOKIPA Pharma Inc. (HOOK) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
HOOK currently has 2.4M outstanding shares. with moderate dilution risk from 485K authorized shares representing 20.2% potential dilution. The company has significantly diluted shareholders by 312.37% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 29, 2025 |
POS AM filing: This is a Post-Effective Amendment to terminate the offering of securities pursuant to the Registration Statement on Form S-3, Registration File No. 333-276220, due to the company's planned liquidation and dissolution, and removes from registration any and all securities of the Company registered for resale but remaining unsold under the Registration Statement. |
2.4M | 480K |
| Jul 29, 2025 |
POS AM filing: This is a Post-Effective Amendment to terminate the offering of securities pursuant to the Registration Statement on Form S-3, Registration File No. 333-266084 due to the Company's planned liquidation and dissolution. |
2.4M | 4.6M |
| May 15, 2025 |
10-Q filing | 2.4M shares outstanding |
2.4M | 4.7M |
| Feb 28, 2025 |
10-K filing | 9.9M shares outstanding |
9.9M | 0 |
| Nov 14, 2024 |
10-Q filing | 2.4M shares outstanding |
2.4M | 4.7M |
| Aug 08, 2024 |
10-Q filing | 2.4M shares outstanding |
2.4M | 4.7M |
| Jul 09, 2024 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 2,399,517 → 9,700,000 |
9.7M | 0 |
| May 09, 2024 |
10-Q filing | 2.4M shares outstanding |
2.4M | 69M |
| Mar 22, 2024 |
10-K filing | 2.4M shares outstanding |
2.4M | 69M |
| Dec 22, 2023 |
S-3 filing: HOOKIPA Pharma Inc. is offering 15,000,000 shares of common stock by the selling stockholder. The shares being offered were issued and sold to Gilead Sciences, Inc., or Gilead, in a private placement that closed on December 20, 2023. |
2.4M | 69M |
| Dec 21, 2023 |
8-K filing: HOOKIPA Pharma Inc. entered into an Amended and Restated Stock Purchase Agreement with Gilead Sciences, Inc., pursuant to which Gilead purchased 15,000,000 unregistered shares of the Company's common stock for approximately $21.25 million at a purchase price of $1.4167 per share. ($21.25M proceeds) |
2.4M | 54M |
| Nov 09, 2023 |
10-Q filing | 2.4M shares outstanding |
2.4M | 54M |
| Aug 10, 2023 |
10-Q filing | 2.4M shares outstanding |
2.4M | 54M |
| Jun 02, 2023 |
8-K filing: HOOKIPA Pharma Inc. entered into an underwriting agreement for a public offering of 22,900,768 shares of common stock at $1.31 per share and 15,268 shares of Series A-2 convertible preferred stock at $1,310.00 per share. |
2.4M | 54M |
| May 11, 2023 |
10-Q filing | 2.4M shares outstanding |
2.4M | 54M |
| Mar 15, 2023 |
10-K filing | 52.3M shares outstanding |
52M | 3.9M |
| Nov 14, 2022 |
10-Q filing | 52.3M shares outstanding |
52M | 3.9M |
| Aug 11, 2022 |
10-Q filing | 50.9M shares outstanding |
51M | 5.3M |
| Jul 12, 2022 |
S-3 filing: Hookipa Pharma Inc. files an S-3 registration statement for the potential offering of common stock, preferred stock, and debt securities, with a total value of up to $200,000,000. |
55M | 1.5M |
| Jul 11, 2022 |
S-3 filing: This S-3 filing relates to the proposed resale of 1,666,666 shares of common stock by a selling stockholder, Gilead Sciences, Inc. The company will not receive any proceeds from the sale. |
1.7M | 27M |
| Jun 22, 2022 |
8-K filing: HOOKIPA Pharma Inc. entered into a registration rights agreement with Gilead Sciences, Inc. pursuant to a Stock Purchase Agreement, where Gilead purchased 1,666,666 shares of the Company's common stock for approximately $5.0 million at $3.00 per share. ($5.0M proceeds) |
27M | 0 |
| May 16, 2022 |
10-Q filing | 27.4M shares outstanding |
27M | 0 |
| Mar 24, 2022 |
10-K filing | 3.8M shares outstanding |
3.8M | 0 |
| Mar 03, 2022 |
8-K filing: HOOKIPA Pharma Inc. executed a public offering of 21,700,000 shares of common stock at $2.00 per share and 15,800 shares of Series A-1 convertible preferred stock at $2,000.00 per share. |
51M | 0 |
| Feb 15, 2022 |
8-K filing: Hookipa Pharma Inc. entered into a Stock Purchase Agreement with Gilead Sciences, where Gilead purchased 1,666,666 shares of Hookipa's common stock for approximately $5.0 million at $3.00 per share as an initial purchase under the agreement. ($5.0M proceeds) |
26M | 1.4M |
| Nov 10, 2021 |
10-Q filing | 25.9M shares outstanding |
26M | 1.4M |
| Aug 12, 2021 |
10-Q filing | 25.9M shares outstanding |
26M | 1.4M |
| May 12, 2021 |
10-Q filing | 26.0M shares outstanding |
26M | 1.4M |
| Mar 18, 2021 |
10-K filing | 26.0M shares outstanding |
26M | 1.4M |
| Dec 11, 2020 |
8-K filing: HOOKIPA Pharma Inc. filed a Certificate of Designation designating 2,978 shares of preferred stock as Series A Convertible Preferred Stock, each convertible into 1,000 shares of the Company's common stock. |
22M | 5.5M |
| Dec 10, 2020 |
8-K filing: HOOKIPA Pharma Inc. entered into an underwriting agreement for a public offering of 3,400,000 shares of common stock at $11.75 per share and 2,978 shares of Series A convertible preferred stock at $11,750.00 per share, with an expected closing date of December 11, 2020. |
22M | 5.5M |
| Nov 12, 2020 |
10-Q filing | 21.9M shares outstanding |
22M | 5.5M |
| Aug 13, 2020 |
10-Q filing | 21.8M shares outstanding |
22M | 5.5M |
| May 15, 2020 |
S-3 filing: The company is filing an S-3 to offer up to $200,000,000 of common stock, preferred stock, and debt securities from time to time. |
26M | 1.7M |
| May 14, 2020 |
10-Q filing | 21.8M shares outstanding |
22M | 0 |
| Mar 19, 2020 |
10-K filing | 21.8M shares outstanding |
22M | 0 |